Can't get Bevacizumab (Avastin)? Learn about alternative anti-VEGF cancer treatments like Ramucirumab, Ziv-Aflibercept, and more.
If you or a loved one has been prescribed Bevacizumab and can't get it — whether due to a shortage, insurance issues, or supply problems at your infusion center — it's natural to feel worried. Your treatment plan is important, and you need to know what comes next.
First, the most important thing: don't stop your treatment without talking to your oncologist. There are alternatives, and your doctor can help you figure out the best path forward based on your specific cancer type and treatment history.
Bevacizumab (brand name Avastin) is a monoclonal antibody — a type of biologic drug made from living cells. It works by blocking a protein called VEGF (vascular endothelial growth factor). Tumors produce VEGF to stimulate the growth of new blood vessels (a process called angiogenesis) that deliver oxygen and nutrients to the tumor.
By blocking VEGF, Bevacizumab cuts off the tumor's blood supply, slowing or stopping its growth. It's used in combination with chemotherapy for many cancer types, including colorectal cancer, lung cancer, kidney cancer, cervical cancer, ovarian cancer, brain tumors (glioblastoma), and liver cancer.
To learn more about how Bevacizumab works at the molecular level, check out our detailed explainer.
Before switching to a completely different medication, remember that there are now six FDA-approved biosimilars of Bevacizumab:
These biosimilars are clinically equivalent to brand-name Avastin. If your facility is out of one, another biosimilar may be available. Use Medfinder to find Bevacizumab in stock near you.
If Bevacizumab is truly unavailable in any form, your oncologist may consider one of these alternative anti-VEGF or anti-angiogenic medications. Keep in mind that these are not identical to Bevacizumab — they have different mechanisms, different approved indications, and different side effect profiles. Only your oncologist can determine which is appropriate for your specific situation.
Ramucirumab is a monoclonal antibody like Bevacizumab, but instead of binding to the VEGF protein itself, it binds to the VEGF receptor (VEGFR-2) on blood vessel cells. This blocks the signal that tells blood vessels to grow.
FDA-approved for:
How it's given: IV infusion every 2 weeks
Key consideration: Ramucirumab may be an option for patients with colorectal cancer, NSCLC, or liver cancer who cannot access Bevacizumab. It carries similar risks of bleeding, hypertension, and GI perforation.
Ziv-Aflibercept is a recombinant fusion protein that acts as a "VEGF trap." It binds to VEGF-A, VEGF-B, and placental growth factor (PlGF) — actually capturing a broader range of growth factors than Bevacizumab.
FDA-approved for:
How it's given: IV infusion every 2 weeks
Key consideration: Ziv-Aflibercept is specifically used for colorectal cancer patients. It has been shown to improve survival even in patients who previously received Bevacizumab. Side effects include hypertension, proteinuria, and bleeding.
Regorafenib is an oral multikinase inhibitor that targets VEGF receptors along with several other growth-promoting kinases. Unlike Bevacizumab, it's taken as a pill, not an infusion.
FDA-approved for:
How it's given: Oral tablet, taken daily for 3 weeks on / 1 week off
Key consideration: Regorafenib is typically used later in the treatment sequence, after Bevacizumab-containing regimens have been tried. The convenience of an oral medication can be appealing, but it has significant side effects including hand-foot syndrome, fatigue, diarrhea, and liver toxicity.
Lenvatinib is another oral multikinase inhibitor that blocks VEGF receptors (VEGFR1-3) plus other kinases involved in tumor growth. It's often used in combination with other cancer drugs.
FDA-approved for:
How it's given: Oral capsule, taken daily
Key consideration: Lenvatinib targets a broader range of cancers and is often used where Bevacizumab isn't indicated. It may be relevant for kidney cancer or liver cancer patients as an alternative approach.
Switching cancer medications is never a decision to make on your own. Each of these alternatives has different:
Your oncologist understands your full medical picture — your cancer type, stage, treatment history, other medications, and overall health. They're the right person to guide this decision.
Not being able to access your prescribed cancer medication is stressful, but you have options. Start by checking if a different Bevacizumab biosimilar is available through Medfinder. If Bevacizumab isn't accessible in any form, talk to your oncologist about Ramucirumab, Ziv-Aflibercept, Regorafenib, or Lenvatinib as potential alternatives.
The most important thing is to keep the conversation going with your care team. Don't skip treatments and don't lose hope — there are paths forward.
For help finding a specialist who prescribes Bevacizumab, visit our guide on how to find a doctor who can prescribe Bevacizumab near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
